Dexcom raises 2026 revenue midpoint and adds a $1.0 billion buyback after 11% Q3 growth
Market Chameleon (Fri, 30-Oct 8:50 AM)
Dexcom’s NEJM-published CONNECT trial shows a 0.9% A1C advantage and near-universal CGM persistence at 26 weeks
Market Chameleon (Thu, 15-Oct 7:07 AM)
Dexcom U hits a record 27-athlete roster as survey shows fewer young adults quit sports after Type 1 diagnosis
Market Chameleon (Wed, 7-Oct 11:49 AM)
